Company news

Sernova Biotherapeutics Inc (TSX:SVA) news

Sernova Biotherapeutics Inc news releases on 6ix. Latest, Oct 5, 2026: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova…

Sernova Biotherapeutics Inc (TSX:SVA) news

Press releases & updates

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference

Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

Sernova Biotherapeutics : 2026 Q1 MD&A

Sernova Biotherapeutics : 2026 Q1 Financial Statements

Sernova Biotherapeutics : Voting Instruction Form (VIF) (SVA 2026 VIF)

Sernova Biotherapeutics : Appointment of Proxyholder (SVA 2026 Proxy)

Sernova Biotherapeutics : Combined Circular with Schedules (SVA 2026 Combined Circular w Schedules)

Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval

Sernova Biotherapeutics Announces Warrant Amendments

Sernova Biotherapeutics : 2025 Q4 MD&A

Sernova Biotherapeutics : 2025 Q4 Financial Statements

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts

Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors

Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

Sernova Biotherapeutics : 2025 Q2 MD&A

Sernova Biotherapeutics : 2025 Q2 Financial Statements

Sernova Appoints Jonathan Rigby as Interim Chair

Chair of Sernova Biotherapeutics Resigns

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch(TM) Bio-Hybrid Organ for Treatment of Type 1 Diabetes

Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes

Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing

Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

Sernova Announces Key New Executive Appointments

Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa

Sernova Appoints David Paterson Ph.D. to its Board of Directors

Sernova to Participate in Upcoming H.C. Wainwright Investor Conference

Sernova Closes $5.2 Million Over-Subscribed Non-Brokered, Private Placement

Sernova Announces Oversubscribed Non-Brokered Private Placement

Sernova Announces Up to $4 Million Private Placement Priced at a Premium

Lead Investigator for Sernova's Clinical Trial with Cell Pouch for Type 1 Diabetes to Deliver Oral Presentation at the 2024 EASD Annual Meeting

Jonathan Rigby Appointed as Executive Chairman for Sernova

Sernova Announces Additional Patient Insulin Independent and Cohort 2 Enrollment Complete in Ongoing Phase I/II Clinical Trial for Treatment of Type 1 Diabetes

Sernova Provides Update on Public Offering

Sernova Announces Marketed Public Offering of Units

Sernova Appoints Jonathan Rigby to its Board of Directors